

NANEXA: 90 Second Pitch with CEO David Westberg

90 Second Pitch with drug delivery company NANEXA (Nasdaq First North) that recently signed a deal with NOVO NORDISK triggering a +100% surge in the share price.

The deal with NOVO NORDISK provided both scientific validation to the PharmaShell platform and investor-friendly financing.

In this Quick Pitch NANEXA CEO David Westberg answers

- What the company does
- Why an investor should look at NANEXA right now
- The most important issues for 2023
- What he expects the company to look like in 3-5 years

See the 90 Second Pitch here https://www.linkedin.com/posts/johan-widmark_nanexa

Contact

Johan Widmark
johan@emergers.se

About Emergers

This is a press release from Emergers.

DISCLAIMER

Information provided here or on Emergers' website emergers.se is not intended to be financial advice. Emergers receives compensation for writing about the company in question. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers' own. Articles of analysis shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot guarantee that the conclusions presented in the analysis will be met. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.

For more information and complete terms, please see emergers.se.

Press Release
23 February 2023 10:30:00 CET



Attachments

[NANEXA: go Second Pitch with CEO David Westberg](#)